TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

This study has been completed.
Information provided by (Responsible Party):
Tibotec Pharmaceuticals, Ireland Identifier:
First received: November 10, 2005
Last updated: June 19, 2014
Last verified: June 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2008
  Primary Completion Date: February 2007 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):